PR1 LEUKEMIA PEPTIDE VACCINE
drug drugOn this page
Also known as Pr1 vacProteinase 3 pr1 peptide
Summary
Pr1 Leukemia Peptide Vaccine (CHEMBL4297811) is a phase-3 clinical-stage vaccine component; indicated across 5 conditions including leukemia and myelodysplastic syndrome.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Vaccine component
- Indications: 5 conditions
- Clinical trials: 3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297811 |
| Name | PR1 LEUKEMIA PEPTIDE VACCINE |
| Type | Vaccine component |
| Max phase | 3 |
Also known as: Pr1 leukemia peptide vaccine, Pr1 vac, Proteinase 3 pr1 peptide, PR1 LEUKEMIA PEPTIDE VACCINE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| leukemia | 3 | MONDO:0005059 | EFO:0000565 |
| myelodysplastic syndrome | 2 | MONDO:0018881 | EFO:0000198 |
| acute myeloid leukemia | 1 | MONDO:0018874 | EFO:0000222 |
| chronic myeloid leukemia | 1 | MONDO:0011996 | EFO:0000339 |
| myelodysplastic syndrome with excess blasts | 1 | MONDO:0019454 | EFO:0003811 |
Clinical trials
Total trials: 3.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00454168 | PHASE3 | UNKNOWN | Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission |
| NCT00004918 | PHASE1/PHASE2 | COMPLETED | Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome |
| NCT00513578 | PHASE2 | UNKNOWN | Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- In clinical trials for: leukemia, myelodysplastic syndrome